Photodynamic Therapy

Advances in Dermatology

Volumn 22, Issue , 2006, Pages 219-258

  MacCormack, Mollie A ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOTOSENSITIZING AGENT;

HUMAN; METHODOLOGY; PHOTOCHEMOTHERAPY; REVIEW; SKIN DISEASE; SKIN TUMOR;

HUMANS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SKIN DISEASES; SKIN NEOPLASMS;

EID: 33845650323     PISSN: 08820880     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yadr.2006.09.008     Document Type: Review

References (207)

1. Roelandts R. The history of phototherapy: something new under the sun?. J Am Acad Dermatol 46 (2002) 926-930
2. Dougherty T.J. A brief history of clinical photodynamic therapy development at Roswell Park Cancer Institute. J Clin Laser Med Surg 14 (1996) 219-221
3. Ackroyd R., Kelty C., Brown N., et al. The history of photodetection and photodynamic therapy. Photochem Photobiol 74 (2001) 656-669
4. Daniell M.D., and Hill J.S. A history of photodynamic therapy. Aust N Z J Surg 61 (1991) 340-348
5. Hausmann W. Die dendibilisierende Wirkung des Hematoporphyrins. Biochem Z 30 (1911) 276-316
6. Meyer-Betz F. Untersuchungen uber die Biologische (photodynamische) Wirkung des Hematoporphyrins und anderer Derivative des Blut- und Galenfarbstoffs. Dtsch Arch Klin Med 112 (1913) 476-503
7. Policard A. Etudes sur les aspects offerts par des tumeurs experimentales examinees a la lumiere de Wood. C R Soc Biol 91 (1924) 1423-1428
8. Schwartz S., Absolon K., and Vermund H. Some relationships of porphyrins, x-rays and tumors. Bull Minnesota Univ School Med 27 (1955) 7-13
9. Lipson R.L., and Baldes E.J. The photodynamic properties of a particular hematoporphyrin derivative. Arch Dermatol 82 (1960) 508-516
10. Lipson R.L., Baldes E.J., and Olsen A.M. The use of a derivative of hematoporphyrin in tumor detection. J Natl Cancer Inst 26 (1961) 1-11
11. Diamond I., Granelli S.G., McDonagh A.F., et al. Photodynamic therapy of malignant tumours. Lancet 2 7788 (1972) 1175-1177
12. Figge F.H., Weiland G.S., and Manganiello O.J. Cancer detection and therapy: affinity of neoplastic, embryonic and traumatized regenerating tissues for porphyrins and metalloporphyrins. Proc Soc Exp Biol Med 68 (1948) 640-641
13. Manganiello L.O.J., and Figge F.H. Cancer detection and therapy: II. methods of preparation and biological effects of metalloporphyrins. Bull Sch Med Univ Md 36 (1951) 3-7
14. Rassmussan-Taxdal D.S., Ward G.E., and Figge F.H. Fluorescence of human lymphatic and cancer tissues following high dose of intravenous hematoporphyrin. Cancer 8 (1955) 78-81
15. Lipson R.L., Baldes E.J., and Gray M.J. Hematoporphryin derivative for the detection and management of cancer. Cancer 20 (1967) 255-257
16. Kyriazis G.A., Balin H., and Lipson R.L. Hematoporphyrin derivative fluorescence test colposcopy and colpophotography in the diagnosis of atypical metaplasia, dysplasia and carcinoma in situ of the cervix uteri. Am J Obstet Gynecol 117 (1973) 375-380
17. Eichler J., Liebetruth J., London R.A., et al. Temperature distribution for combined laser hyperthermia-photodynamic therapy in the esophagus. Med Eng Phys 22 (2000) 307-312
18. Dougherty T.J. Photoradiation therapy for the treatment of malignant tumors. Cancer Res 36 (1978) 2628-2635
19. LoCicero III J., Metzdorff M., and Almgren C. Photodynamic therapy in the palliation of late stage obstructing non-small cell lung cancer. Chest 98 (1990) 97-100
20. Balchum O.J., Doiron D.R., and Huth G.C. Photoradiation therapy of endobronchial lung cancers employing the photodynamic action of hematoporphyrin derivative. Lasers Surg Med 4 (1984) 13-30
21. Lam S., Muller N.L., Miller R.R., et al. Predicting the response of obstructive endobronchial tumors to photodynamic therapy. Cancer 58 (1986) 2298-2306
22. Kelly J.F., Snell M.E., and Berenbaum M.C. Photodynamic destruction of human bladder carcinoma. Br J Cancer 31 (1975) 237-244
23. Prout Jr. G.R., Lin C.W., Benson Jr. R., et al. Photodynamic therapy with hematoporphyrin derivative in the treatment of superficial transitional-cell carcinoma of the bladder. N Engl J Med 317 (1987) 1251-1255
24. McCaughan Jr. J.S., Williams Jr. T.E., and Bethel B.H. Palliation of esophageal malignancy with photodynamic therapy. Ann Thorac Surg 40 (1985) 113-120
25. Hayata Y., Kato H., Okitsu H., et al. Photodynamic therapy with hematoporphyrin derivative in cancer of the upper gastrointestinal tract. Semin Surg Oncol 1 (1985) 1-11
26. Sibille A., Lambert R., Souquet J.C., et al. Long-term survival after photodynamic therapy for esophageal cancer. Gastroenterology 108 (1995) 337-344
27. Ward B.G., Forbes I.J., Cowled P.A., et al. The treatment of vaginal recurrences of gynecological malignancy with phototherapy following hematoporphyrin derivative pre-treatment. Am J Obstet Gynecol 142 (1982) 356-357
28. Kaye A.H., and Hill J.S. Photodynamic therapy of brain tumours. Ann Acad Med Singapore 22 3 Suppl (1993) 470-481
29. Barr H., Krasner N., Boulos P.B., et al. Photodynamic therapy for colorectal cancer: a quantitative pilot study. Br J Surg 77 (1990) 93-96
30. Gomer C.J., Jester J.V., Razum N.J., et al. Photodynamic therapy of intraocular tumors: examination of hematoporphyrin derivative distribution and long-term damage in rabbit ocular tissue. Cancer Res 45 (1985) 3718-3725
31. Bellnier D.A., and Dougherty T.J. A preliminary pharmacokinetic study of intravenous Photofrin in patients. J Clin Laser Med Surg 14 (1996) 311-314
32. Divaris D.X.G., Kennedy J.C., and Pottier R.H. Phototoxic damage to sebaceous glands and hair follicles of mice after systemic administration of 5-aminolevulinic acid correlates with localized protoporphyrin Ix fluorescence. Am J Pathol 136 (1990) 891-897
33. Kennedy J.C., and Pottier R.H. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 14 (1992) 275-292
34. Kennedy J.C., Pottier R.H., and Pross D.C. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 6 (1990) 143-148
35. Taylor E.L., and Brown S.B. The advantages of aminolevulinic acid photodynamic therapy in dermatology. J Dermatol Treat 13 Suppl 1 (2002) S3-S11
36. Korbelik M., Krosl G., Krosl J., et al. The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. Cancer Res 56 (1996) 5647-5652
37. Cecic I., and Korbelik M. Mediators of peripheral blood neutrophilia induced by photodynamic therapy of solid tumors. Cancer Lett 183 (2002) 43-51
38. Korbelik M. Induction of tumor immunity by photodynamic therapy. J Clin Laser Med Surg 14 (1996) 329-334
39. Korbelik M., and Krosl G. Enhanced macrophage cytotoxicity against tumor cells treated with photodynamic therapy. Photochem Photobiol 60 (1994) 497-502
40. Korbelik M., and Cecic I. Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett 137 (1999) 91-98
41. Granville D.J., McManus B.M., and Hunt D.W. Photodynamic therapy: shedding light on the biochemical pathways regulating porphyrin-mediated cell death. Histol Histopathol 16 (2001) 309-317
42. Reed M.W., Wieman T.J., Doak K.W., et al. The microvascular effects of photodynamic therapy: evidence for a possible role of cyclooxygenase products. Photochem Photobiol 50 (1989) 419-423
43. Fingar V.H. Vascular effects of photodynamic therapy. J Clin Laser Med Surg 14 (1996) 323-328
44. Oleinick N.L., and Evans H.H. The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat Res 150 5 Suppl (1998) S146-S156
45. Gomer C.J., Ferrario A., Hayashi N., et al. Molecular, cellular, and tissue responses following photodynamic therapy. Lasers Surg Med 8 (1988) 450-463
46. Agarwal M.L., Clay M.E., Harvey E.J., et al. Photodynamic therapy induces rapid cell death by apoptosis in L5178Y mouse lymphoma cells. Cancer Res 51 (1991) 5993-5996
47. Nakaseko H., Kobayashi M., Akita Y., et al. Histological changes and involvement of apoptosis after photodynamic therapy for actinic keratoses. Br J Dermatol 148 (2003) 122-127
48. Matsumoto Y., Muro Y., Banno S., et al. Differential apoptotic pattern induced by photodynamic therapy and cisplatin in human squamous cell carcinoma cell line. Arch Dermatol Res 289 (1996) 52-54
49. Verma A., Facchina S.L., Hirsch D.J., et al. Photodynamic tumor therapy: mitochondrial benzodiazepine receptors as a therapeutic target. Mol Med 4 (1998) 40-45
50. Granville D.J., Cassidy B.A., Ruehlmann D.O., et al. Mitochondrial release of apoptosis-inducing factor and cytochrome c during smooth muscle cell apoptosis. Am J Pathol 159 (2001) 305-311
51. Granville D.J., Carthy C.M., Jiang H., et al. Rapid cytochrome c release, activation of caspases 3, 6, 7 and 8 followed by Bap31 cleavage in HeLa cells treated with photodynamic therapy. FEBS Lett 437 (1998) 5-10
52. Granville D.J., Levy J.G., and Hunt D.W. Photodynamic therapy induces caspase-3 activation in HL-60 cells. Cell Death Differ 4 (1997) 623-628
53. Porter A.G., and Janicke R.U. Emerging role of caspase-3 in apoptosis. Cell Death Differ 6 (1999) 99-104
54. He J., Agarwal M.L., Larkin H.E., et al. The induction of partial resistance to photodynamic therapy by the protooncogene BCL-2. Photochem Photobiol 64 (1996) 845-852
55. Granville D.J., Jiang H., An M.T., et al. Bcl-2 overexpression blocks caspase activation and downstream apoptotic events instigated by photodynamic therapy. Br J Cancer 79 (1999) 95-100
56. Kim H.R., Luo Y., Li G., et al. Enhanced apoptotic response to photodynamic therapy after bcl-2 transfection. Cancer Res 59 (1999) 3429-3432
57. Zhou C.N. Mechanisms of tumor necrosis induced by photodynamic therapy. J Photochem Photobiol B 3 (1989) 299-318
58. Middelkamp-Hup M.A., Sanchez-Carpintero I., Kossodo S., et al. Photodynamic therapy for cutaneous proliferative vascular tumors in a mouse model. J Invest Dermatol 121 (2003) 634-639
59. Steluti R., De Rosa F.S., Collett J., et al. Topical glycerol monooleate/propylene glycol formulations enhance 5-aminolevulinic acid in vitro skin delivery and in vivo protophorphyrin IX accumulation in hairless mouse skin. Eur J Pharm Biopharm 60 (2005) 439-444
60. Bender J., Ericson M.B., Merclin N., et al. Lipid cubic phases for improved topical drug delivery in photodynamic therapy. J Control Release 106 (2005) 350-360
61. Ziolkowski P., Osiecka B.J., Oremek G., et al. Enhancement of photodynamic therapy by use of aminolevulinic acid/glycolic acid drug mixture. J Exp Ther Oncol 4 (2004) 121-129
62. Korbelik M., Naraparaju V.R., and Yamamoto N. Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer. Br J Cancer 75 (1997) 202-207
63. Korbelik M., Sun J., and Posakony J.J. Interaction between photodynamic therapy and BCG immunotherapy responsible for the reduced recurrence of treated mouse tumors. Photochem Photobiol 73 (2001) 403-409
64. Bellnier D.A., Gollnick S.O., Camacho S.H., et al. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors. Cancer Res 63 (2003) 7584-7590
65. Bellnier D.A. Potentiation of photodynamic therapy in mice with recombinant human tumor necrosis factor-alpha. J Photochem Photobiol B 8 (1991) 203-210
66. Ferrario A., von Tiehl K.F., Rucker N., et al. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 60 (2000) 4066-4069
67. Ferrario A., Chantrain C.F., von Tiehl K., et al. The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Cancer Res 64 (2004) 2328-2332
68. Ferrario A., Von Tiehl K., Wong S., et al. Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res 62 (2002) 3956-3961
69. Korbelik M., Sun J., Cecic I., et al. Adjuvant treatment for complement activation increases the effectiveness of photodynamic therapy of solid tumors. Photochem Photobiol Sci 3 (2004) 812-816
70. Peng Q., Warloe T., Berg K., et al. 5-Aminolevulinic acid-based photodynamic therapy: clinical research and future challenges. Cancer 79 (1997) 2282-2308
71. Jeffes E.W., McCullough J.L., Weinstein G.D., et al. Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light. J Am Acad Dermatol 45 (2001) 96-104
72. Jeffes E.W., McCullough J.L., Weinstein G.D., et al. Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid: a pilot dose-ranging study. Arch Dermatol 133 (1997) 727-732
73. Smith S., Piacquadio D., Morhenn V., et al. Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol 2 (2003) 629-635
74. Ruiz-Rodriguez R., Sanz-Sanchez T., and Cordoba S. Photodynamic photorejuvenation. Dermatol Surg 28 (2002) 742-744 [discussion: 744]
75. Regula J., MacRobert A.J., Gorchein A., et al. Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX-a pilot study. Gut 36 (1995) 67-75
76. Dalton J.T., Meyer M.C., and Golub A.L. Pharmacokinetics of aminolevulinic acid after oral and intravenous administration in dogs. Drug Metab Dispos 27 (1999) 432-435
77. Fritsch C., Homey B., Stahl W., et al. Preferential relative porphyrin enrichment in solar keratoses upon topical application of delta-aminolevulinic acid methylester. Photochem Photobiol 68 (1998) 218-221
78. Morton C.A. Methyl aminolaevulinate photodynamic therapy for Bowen's disease: a practical option?. Australas J Dermatol 46 Suppl (2005) S21-S22 [discussion: S23-5]
79. Gayl Schweitzer V. Photofrin-mediated photodynamic therapy for treatment of aggressive head and neck nonmelanomatous skin tumors in elderly patients. Laryngoscope 111 (2001) 1091-1098
80. Wilson B.D., Mang T.S., Stoll H., et al. Photodynamic therapy for the treatment of basal cell carcinoma. Arch Dermatol 128 (1992) 1597-1601
81. Bernstein Z.P., Wilson B.D., Oseroff A.R., et al. Photofrin photodynamic therapy for treatment of AIDS-related cutaneous Kaposi's sarcoma. AIDS 13 (1999) 1697-1704
82. Detty M.R., Gibson S.L., and Wagner S.J. Current clinical and preclinical photosensitizers for use in photodynamic therapy. J Med Chem 47 (2004) 3897-3915
83. Sharman W.M., Allen C.M., and van Lier J.E. Photodynamic therapeutics: basic principles and clinical applications. Drug Discov Today 4 (1999) 507-517
84. Chan W.S., Svensen R., Phillips D., et al. Cell uptake, distribution and response to aluminium chloro sulphonated phthalocyanine, a potential anti-tumour photosensitizer. Br J Cancer 53 (1986) 255-263
85. Pope A.J., and Bown S.G. The morphological and functional changes in rat bladder following photodynamic therapy with phthalocyanine photosensitization. J Urol 145 (1991) 1064-1070
86. Kostenich G.A., Zhuravkin I.N., and Zhavrid E.A. Experimental grounds for using chlorin e6 in the photodynamic therapy of malignant tumors. J Photochem Photobiol B 22 (1994) 211-217
87. Rifkin R., Reed B., Hetzel F., et al. Photodynamic therapy using SnET2 for basal cell nevus syndrome: a case report. Clin Ther 19 (1997) 639-641
88. Maugain E., Sasnouski S., Zorin V., et al. Foscan-based photodynamic treatment in vivo: correlation between efficacy and Foscan accumulation in tumor, plasma and leukocytes. Oncol Rep 12 (2004) 639-645
89. Berenbaum M.C., Hall G.W., and Hoyes A.D. Cerebral photosensitisation by haematoporphyrin derivative: evidence for an endothelial site of action. Br J Cancer 53 (1986) 81-89
90. Kubler A.C., Haase T., Staff C., et al. Photodynamic therapy of primary nonmelanomatous skin tumours of the head and neck. Lasers Surg Med 25 (1999) 60-68
91. Kubler A.C., de Carpentier J., Hopper C., et al. Treatment of squamous cell carcinoma of the lip using Foscan-mediated photodynamic therapy. Int J Oral Maxillofac Surg 30 (2001) 504-509
92. Lui H., Hobbs L., Tope W.D., et al. Photodynamic therapy of multiple nonmelanoma skin cancers with verteporfin and red light-emitting diodes: two-year results evaluating tumor response and cosmetic outcomes. Arch Dermatol 140 (2004) 26-32
93. Lui H. Photodynamic therapy in dermatology with porfimer sodium and benzoporphyrin derivative: an update. Semin Oncol 21 Suppl 15 (1994) 11-14
94. Sessler J.L., and Miller R.A. Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem Pharmacol 59 (2000) 733-739
95. Ceburkov O., and Gollnick H. Photodynamic therapy in dermatology. Eur J Dermatol 10 (2000) 568-575 [discussion: 576]
96. Salva K.A. Photodynamic therapy: unapproved uses, dosages, or indications. Clin Dermatol 20 (2002) 571-581
97. Alexiades-Armenakas M. Intense pulsed light-mediated photodynamic therapy. J Drugs Dermatol 4 (2005) 657-658
98. Kim H.S., Yoo J.Y., Cho K.H., et al. Topical photodynamic therapy using intense pulsed light for treatment of actinic keratosis: clinical and histopathologic evaluation. Dermatol Surg 31 (2005) 33-36 [discussion: 36-7]
99. Santos M.A., Belo V.G., and Santos G. Effectiveness of photodynamic therapy with topical 5-aminolevulinic acid and intense pulsed light versus intense pulsed light alone in the treatment of acne vulgaris: comparative study. Dermatol Surg 31 Pt 1 (2005) 910-915
100. Calzavara-Pinton P.G., Szeimies R.M., Ortel B., et al. Photodynamic therapy with systemic administration of photosensitizers in dermatology. J Photochem Photobiol B 36 (1996) 225-231
101. Wolf P., Rieger E., and Kerl H. Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid: an alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas?. J Am Acad Dermatol 28 (1993) 17-21
102. Calzavara-Pinton P.G. Repetitive photodynamic therapy with topical delta-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. J Photochem Photobiol B 29 (1995) 53-57
103. Morton C.A., Whitehurst C., Moseley H., et al. Development of an alternative light source to laser for photodynamic therapy: 1. clinical evaluation in the treatment of non-melanoma skin cancer. Lasers Med Sci 10 (1995) 165-171
104. Fijan S., Honigsmann H., and Ortel B. Photodynamic therapy of epithelial skin tumours using delta-aminolaevulinic acid and desferrioxamine. Br J Dermatol 133 (1995) 282-288
105. Szeimies R.M., Karrer S., Sauerwald A., et al. Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study. Dermatology 192 (1996) 246-251
106. Fink-Puches R., Hofer A., Smolle J., et al. Primary clinical response and long-term follow-up of solar keratoses treated with topically applied 5-aminolevulinic acid and irradiation by different wave bands of light. J Photochem Photobiol B 41 (1997) 145-151
107. Kurwa H.A., Yong-Gee S.A., Seed P.T., et al. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol 41 Pt 1 (1999) 414-418
108. Goldman M., and Atkin D. ALA/PDT in the treatment of actinic keratosis: spot versus confluent therapy. J Cosmet Laser Ther 5 (2003) 107-110
109. Touma D., Yaar M., Whitehead S., et al. A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch Dermatol 140 (2004) 33-40
110. Avram D.K., and Goldman M.P. Effectiveness and safety of ALA-IPL in treating actinic keratoses and photodamage. J Drugs Dermatol 3 Suppl (2004) S36-S39
111. Marcus L. Photodynamic therapy for actinic keratosis followed by 5-fluorouracil reaction. Dermatol Surg 29 (2003) 1061-1064 [discussion: 1064-5]
112. Szeimies R.M., Karrer S., Radakovic-Fijan S., et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 47 (2002) 258-262
113. Dragieva G., Prinz B.M., Hafner J., et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol 151 (2004) 196-200
114. Pariser D.M., Lowe N.J., Stewart D.M., et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol 48 (2003) 227-232
115. Freeman M., Vinciullo C., Francis D., et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatol Treat 14 (2003) 99-106
116. Alexiades-Armenakas M.R., and Geronemus R.G. Laser-mediated photodynamic therapy of actinic cheilitis. J Drugs Dermatol 3 (2004) 548-551
117. Stender I.M., and Wulf H.C. Photodynamic therapy with 5-aminolevulinic acid in the treatment of actinic cheilitis. Br J Dermatol 135 (1996) 454-456
118. Wong T.W., Sheu H.M., Lee J.Y., et al. Photodynamic therapy for Bowen's disease (squamous cell carcinoma in situ) of the digit. Dermatol Surg 27 (2001) 452-456
119. Cairnduff F., Stringer M.R., Hudson E.J., et al. Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. Br J Cancer 69 (1994) 605-608
120. Svanberg K., Andersson T., Killander D., et al. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-amino levulinic acid sensitization and laser irradiation. Br J Dermatol 130 (1994) 743-751
121. Morton C.A., Whitehurst C., Moseley H., et al. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br J Dermatol 135 (1996) 766-771
122. Wennberg A.M., Lindholm L.E., Alpsten M., et al. Treatment of superficial basal cell carcinomas using topically applied delta-aminolaevulinic acid and a filtered xenon lamp. Arch Dermatol Res 288 (1996) 561-564
123. Stables G.I., Stringer M.R., Robinson D.J., et al. Large patches of Bowen's disease treated by topical aminolaevulinic acid photodynamic therapy. Br J Dermatol 136 (1997) 957-960
124. Morton C.A., Whitehurst C., Moore J.V., et al. Comparison of red and green light in the treatment of Bowen's disease by photodynamic therapy. Br J Dermatol 143 (2000) 767-772
125. Varma S., Wilson H., Kurwa H.A., et al. Bowen's disease, solar keratoses and superficial basal cell carcinomas treated by photodynamic therapy using a large-field incoherent light source. Br J Dermatol 144 (2001) 567-574
126. Salim A., Leman J.A., McColl J.H., et al. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. Br J Dermatol 148 (2003) 539-543
127. Dragieva G., Hafner J., Dummer R., et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation 77 (2004) 115-121
128. Dijkstra A.T., Majoie I.M., van Dongen J.W., et al. Photodynamic therapy with violet light and topical 6-aminolaevulinic acid in the treatment of actinic keratosis, Bowen's disease and basal cell carcinoma. J Eur Acad Dermatol Venereol 15 (2001) 550-554
129. Stables G.I., Stringer M.R., Robinson D.J., et al. Erythroplasia of Queyrat treated by topical aminolaevulinic acid photodynamic therapy. Br J Dermatol 140 (1999) 514-517
130. Varma S., Holt P.J., and Anstey A.V. Erythroplasia of Queyrat treated by topical aminolaevulinic acid photodynamic therapy: a cautionary tale. Br J Dermatol 142 (2000) 825-826
131. Lee M.R., and Ryman W. Erythroplasia of Queyrat treated with topical methyl aminolevulinate photodynamic therapy. Australas J Dermatol 46 (2005) 196-198
132. Horn M., Wolf P., Wulf H.C., et al. Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br J Dermatol 149 (2003) 1242-1249
133. Rhodes L.E., de Rie M., Enstrom Y., et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol 140 (2004) 17-23
134. Soler A.M., Warloe T., Berner A., et al. A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolaevulinate-based photodynamic therapy alone and with prior curettage. Br J Dermatol 145 (2001) 467-471
135. Itoh Y., Henta T., Ninomiya Y., et al. Repeated 5-aminolevulinic acid-based photodynamic therapy following electro-curettage for pigmented basal cell carcinoma. J Dermatol 27 (2000) 10-15
136. Fink-Puches R., Soyer H.P., Hofer A., et al. Long-term follow-up and histological changes of superficial nonmelanoma skin cancers treated with topical delta-aminolevulinic acid photodynamic therapy. Arch Dermatol 134 (1998) 821-826
137. Lui H., Salasche S., Kollias N., et al. Photodynamic therapy of nonmelanoma skin cancer with topical aminolevulinic acid: a clinical and histologic study. Arch Dermatol 131 (1995) 737-738
138. Moore J.V., and Allan E. Pulsed ultrasound measurements of depth and regression of basal cell carcinomas after photodynamic therapy: relationship to probability of 1-year local control. Br J Dermatol 149 (2003) 1035-1040
139. Soler A.M., Warloe T., Tausjo J., et al. Photodynamic therapy by topical aminolevulinic acid, dimethylsulphoxide and curettage in nodular basal cell carcinoma: a one-year follow-up study. Acta Derm Venereol 79 (1999) 204-206
140. Thissen M.R., Schroeter C.A., and Neumann H.A. Photodynamic therapy with delta-aminolaevulinic acid for nodular basal cell carcinomas using a prior debulking technique. Br J Dermatol 142 (2000) 338-339
141. Wang I., Bendsoe N., Klinteberg C.A., et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 144 (2001) 832-840
142. Kuijpers D.I., Smeets N.W., Krekels G.A., et al. Photodynamic therapy as adjuvant treatment of extensive basal cell carcinoma treated with Mohs micrographic surgery. Dermatol Surg 30 (2004) 794-798
143. Oseroff A.R., Shieh S., Frawley N.P., et al. Treatment of diffuse basal cell carcinomas and basaloid follicular hamartomas in nevoid basal cell carcinoma syndrome by wide-area 5-aminolevulinic acid photodynamic therapy. Arch Dermatol 141 (2005) 60-67
144. Itkin A., and Gilchrest B.A. delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome. Dermatol Surg 30 (2004) 1054-1061
145. Chapas A.M., and Gilchrest B.A. Broad area photodynamic therapy for treatment of multiple basal cell carcinomas in a patient with nevoid basal cell carcinoma syndrome. J Drugs Dermatol 5 Suppl (2006) 3-5
146. Sigurdsson V., Knulst A.C., and Van Weelden H. Phototherapy of acne vulgaris with visible light. Dermatology 194 (1997) 256-260
147. Ashkenazi H., Malik Z., Harth Y., et al. Eradication ofPropionibacterium acnes by its endogenic porphyrins after illumination with high intensity blue light. FEMS Immunol Med Microbiol 35 (2003) 17-24
148. Kjeldstad B. Photoinactivation ofPropionibacterium acnes by near-ultraviolet light. Z Naturforsch [C] 39 (1984) 300-302
149. Meffert H., Gaunitz K., Gutewort T., et al. [Therapy of acne with visible light: decreased irradiation time by using a blue-light high-energy lamp]. Dermatol Monatsschr 176 (1990) 597-603
150. Tzung T., Wu K., and Huang M. Blue light phototherapy in the treatment of acne. Photodermatol Photoimmunol Photomed 20 (2004) 266-269
151. Papageorgiou P., Katsambas A., and Chu A. Phototherapy with blue (415nm) and red (660nm) light in the treatment of acne vulgaris. Br J Dermatol 142 (2000) 973
152. Gold M.H., Rao J., Goldman M.P., et al. A multicenter clinical evaluation of the treatment of mild to moderate inflammatory acne vulgaris of the face with visible blue light in comparison to topical 1% clindamycin antibiotic solution. J Drugs Dermatol 4 (2005) 64-70
153. Hongcharu W., Taylor C.R., Chang Y., et al. Topical ALA-photodynamic therapy for the treatment of acne vulgaris. J Invest Dermatol 115 (2000) 183-192
154. Pollock B., Turner D., Stringer M.R., et al. Topical aminolaevulinic acid-photodynamic therapy for the treatment of acne vulgaris: a study of clinical efficacy and mechanism of action. Br J Dermatol 151 (2004) 616-622
155. Itoh Y., Ninomiya Y., Tajima S., et al. Photodynamic therapy of acne vulgaris with topical delta-aminolaevulinic acid and incoherent light in Japanese patients. Br J Dermatol 144 (2001) 575-579
156. Goldman M.P., and Boyce S.M. A single-center study of aminolevulinic acid and 417 NM photodynamic therapy in the treatment of moderate to severe acne vulgaris. J Drugs Dermatol 2 (2003) 393-396
157. Taub A.F. Photodynamic therapy for the treatment of acne: a pilot study. J Drugs Dermatol 3 Suppl (2004) S10-S14
158. Alexiades-Armenakas M. Long-pulsed dye laser-mediated photodynamic therapy combined with topical therapy for mild to severe comedomal, inflammatory, or cystic acne. J Drugs Dermatol 5 (2006) 45-55
159. Alster T.S., and Tanzi E.L. Photodynamic therapy with topical aminolevulinic acid and pulsed dye laser irradiation for sebaceous hyperplasia. J Drugs Dermatol 2 (2003) 501-504
160. Richey D.F., and Hopson B. Treatment of sebaceous hyperplasia with photodynamic therapy. Cosmetic Dermatol 17 (2004) 525-529
161. Horio T., Horio O., Miyauchi-Hashimoto H., et al. Photodynamic therapy of sebaceous hyperplasia with topical 5-aminolaevulinic acid and slide projector. Br J Dermatol 148 (2003) 1274-1276
162. Dierickx C.C., Goldenhersh M., Dwyer P., et al. Photodynamic therapy for nevus sebaceus with topical delta-aminolevulinic acid. Arch Dermatol 135 (1999) 637-640
163. Goldman M.P., Atkin D., and Kincaid S. PDT/ALA in the treatment of actinic damage: real world experience. Lasers Surg Med 14S (2002) 79
164. Alster T.S., Tanzi E.L., and Welsh E.C. Photorejuvenation of facial skin with topical 20% 5-aminolevulinic acid and intense pulsed light treatment: a split-face comparison study. J Drugs Dermatol 4 (2005) 35-38
165. Ammann R., Hunziker T., and Braathen L.R. Topical photodynamic therapy in verrucae: a pilot study. Dermatology 191 (1995) 346-347
166. Stender I.M., Na R., Fogh H., et al. Photodynamic therapy with 5-aminolaevulinic acid or placebo for recalcitrant foot and hand warts: randomised double-blind trial. Lancet 355 (2000) 963-966
167. Fabbrocini G., Di Costanzo M.P., Riccardo A.M., et al. Photodynamic therapy with topical delta-aminolaevulinic acid for the treatment of plantar warts. J Photochem Photobiol B 61 (2001) 30-34
168. Schroeter C.A., van Pleunis J., Nispen tot Pannerden C., et al. Photodynamic therapy: new treatment for therapy-resistant plantar warts. Dermatol Surg 31 (2005) 71-75
169. Stender I.M., Lock-Andersen J., and Wulf H.C. Recalcitrant hand and foot warts successfully treated with photodynamic therapy with topical 5-aminolaevulinic acid: a pilot study. Clin Exp Dermatol 24 (1999) 154-159
170. Ross E.V., Romero R., Kollias N., et al. Selectivity of protoporphyrin IX fluorescence for condylomata after topical application of 5-aminolaevulinic acid: implications for photodynamic treatment. Br J Dermatol 137 (1997) 736-742
171. Wang X.L., Wang H.W., Wang H.S., et al. Topical 5-aminolaevulinic acid-photodynamic therapy for the treatment of urethral condylomata acuminata. Br J Dermatol 151 (2004) 880-885
172. Fehr M.K., Hornung R., Degen A., et al. Photodynamic therapy of vulvar and vaginal condyloma and intraepithelial neoplasia using topically applied 5-aminolevulinic acid. Lasers Surg Med 30 (2002) 273-279
173. Shieh S., Dee A.S., Cheney R.T., et al. Photodynamic therapy for the treatment of extramammary Paget's disease. Br J Dermatol 146 (2002) 1000-1005
174. Mikasa K., Watanabe D., Kondo C., et al. 5-Aminolevulinic acid-based photodynamic therapy for the treatment of two patients with extramammary Paget's disease. J Dermatol 32 (2005) 97-101
175. Zawislak A.A., McCarron P.A., McCluggage W.G., et al. Successful photodynamic therapy of vulval Paget's disease using a novel patch-based delivery system containing 5-aminolevulinic acid. Br J Obstet Gynaecol 111 (2004) 1143-1145
176. Henta T., Itoh Y., Kobayashi M., et al. Photodynamic therapy for inoperable vulval Paget's disease using delta-aminolaevulinic acid: successful management of a large skin lesion. Br J Dermatol 141 (1999) 347-349
177. Coors E.A., and von den Driesch P. Topical photodynamic therapy for patients with therapy-resistant lesions of cutaneous T-cell lymphoma. J Am Acad Dermatol 50 (2004) 363-367
178. Orenstein A., Haik J., Tamir J., et al. Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application. Dermatol Surg 26 (2000) 765-769 [discussion: 769-70]
179. Paech V., Lorenzen T., Stoehr A., et al. Remission of a cutaneous mycosis fungoides after topical 5-ALA sensitisation and photodynamic therapy in a patient with advanced HIV-infection. Eur J Med Res 7 (2002) 477-479
180. Edstrom D.W., Porwit A., and Ros A.M. Photodynamic therapy with topical 5-aminolevulinic acid for mycosis fungoides: clinical and histological response. Acta Derm Venereol 81 (2001) 184-188
181. Markham T., Sheahan K., and Collins P. Topical 5-aminolaevulinic acid photodynamic therapy for tumour-stage mycosis fungoides. Br J Dermatol 144 (2001) 1262-1263
182. Bissonnette R., Tremblay J.F., Juzenas P., et al. Systemic photodynamic therapy with aminolevulinic acid induces apoptosis in lesional T lymphocytes of psoriatic plaques. J Invest Dermatol 119 (2002) 77-83
183. Collins P., Robinson D.J., Stringer M.R., et al. The variable response of plaque psoriasis after a single treatment with topical 5-aminolaevulinic acid photodynamic therapy. Br J Dermatol 137 (1997) 743-749
184. Robinson D.J., Collins P., Stringer M.R., et al. Improved response of plaque psoriasis after multiple treatments with topical 5-aminolaevulinic acid photodynamic therapy. Acta Derm Venereol 79 (1999) 451-455
185. Radakovic-Fijan S., Blecha-Thalhammer U., Schleyer V., et al. Topical aminolaevulinic acid-based photodynamic therapy as a treatment option for psoriasis? Results of a randomized, observer-blinded study. Br J Dermatol 152 (2005) 279-283
186. Stender I.M., and Wulf H.C. Kobner reaction induced by photodynamic therapy using delta-aminolevulinic acid: a case report. Acta Derm Venereol 76 (1996) 392-393
187. Kirby B., Whitehurst C., Moore J.V., et al. Treatment of lichen planus of the penis with photodynamic therapy. Br J Dermatol 141 (1999) 765-766
188. Hillemanns P., Untch M., Prove F., et al. Photodynamic therapy of vulvar lichen sclerosus with 5-aminolevulinic acid. Obstet Gynecol 93 (1999) 71-74
189. Hillemanns P., Untch M., Dannecker C., et al. Photodynamic therapy of vulvar intraepithelial neoplasia using 5-aminolevulinic acid. Int J Cancer 85 (2000) 649-653
190. Karrer S., Abels C., Wimmershoff M.B., et al. Successful treatment of cutaneous sarcoidosis using topical photodynamic therapy. Arch Dermatol 138 (2002) 581-584
191. Ruiz-Rodriguez R., Alvarez J.G., Jaen P., et al. Photodynamic therapy with 5-aminolevulinic acid for recalcitrant familial benign pemphigus (Hailey-Hailey disease). J Am Acad Dermatol 47 (2002) 740-742
192. Exadaktylou D., Kurwa H.A., Calonje E., et al. Treatment of Darier's disease with photodynamic therapy. Br J Dermatol 149 (2003) 606-610
193. Karrer S., Abels C., Landthaler M., et al. Topical photodynamic therapy for localized scleroderma. Acta Derm Venereol 80 (2000) 26-27
194. Schmook T., Budde K., Ulrich C., et al. Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. Nephrol Dial Transplant 20 (2005) 220-222
195. Moiin A. Photodynamic therapy for molluscum contagiosum infection in HIV-coinfected patients: review of 6 patients. J Drugs Dermatol 2 (2003) 637-639
196. Gold M.H., Boring M.M., Bridges T.M., et al. The successful use of ALA-PDT in the treatment of recalcitrant molluscum contagiosum. J Drugs Dermatol 3 (2004) 187-190
197. Stender I.M., Bech-Thomsen N., Poulsen T., et al. Photodynamic therapy with topical delta-aminolevulinic acid delays UV photocarcinogenesis in hairless mice. Photochem Photobiol 66 (1997) 493-496
198. Bissonette R., Bergeron A., and Liu Y. Large surface photodynamic therapy with aminolevulinic acid: treatment of actinic keratoses and beyond. J Drugs Dermatol 3 Suppl (2004) S26-S31
199. Wolf P., Fink-Puches R., Reimann-Weber A., et al. Development of malignant melanoma after repeated topical photodynamic therapy with 5-aminolevulinic acid at the exposed site. Dermatology 194 (1997) 53-54
200. Alexiades-Armenakas M.R., and Geronemus R.G. Laser-mediated photodynamic therapy of actinic keratoses. Arch Dermatol 139 (2003) 1313-1320
201. Piacquadio D.J., Chen D.M., Farber H.F., et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol 140 (2004) 41-46
202. Orenstein A., Kostenich G., Tsur H., et al. Temperature monitoring during photodynamic therapy of skin tumors with topical 5-aminolevulinic acid application. Cancer Lett 93 (1995) 227-232
203. Hurlimann A.F., Hanggi G., and Panizzon R.G. Photodynamic therapy of superficial basal cell carcinomas using topical 5-aminolevulinic acid in a nanocolloid lotion. Dermatology 197 (1998) 248-254
204. Fink-Puches R., Wolf P., and Kerl H. Photodynamic therapy of superficial basal cell carcinoma by instillation of aminolevulinic acid and irradiation with visible light. Arch Dermatol 133 (1997) 1494-1495
205. Harth Y., Hirshowitz B., and Kaplan B. Modified topical photodynamic therapy of superficial skin tumors, utilizing aminolevulinic acid, penetration enhancers, red light, and hyperthermia. Dermatol Surg 24 (1998) 723-726
206. Morton C.A., and Burden A.D. Treatment of multiple scalp basal cell carcinomas by photodynamic therapy. Clin Exp Dermatol 26 (2001) 33-36
207. Morton C.A., Whitehurst C., McColl J.H., et al. Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol 137 (2001) 319-324